GTB-3650

N/A

Report date: 2024/12/17 14:20:59

Base Information

Drug NameGTB-3650

Drug Alias NameAnti-CD16/IL-15/Anti-CD33OXS-C3550 TriKEAnti-CD16-IL-15-anti-CD33 TriKEGTB-3650GTB-360 +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)

Mechanisms of ActionAnti-IL15Anti-Myeloid cell surface antigen CD33Anti-Low affinity immunoglobulin gamma Fc region receptor III-A

TargetsInterleukin-15Myeloid cell surface antigen CD33Low affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsMyelodysplastic SyndromesBone Marrow NeoplasmsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMasonic Cancer Center, University Of Minnesota

China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesBone Marrow NeoplasmsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A